Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aclaris Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRS
Nasdaq
2834
www.aclaristx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aclaris Therapeutics, Inc.
Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection
- Nov 16th, 2026 4:34 pm
Aclaris stock falls after atopic dermatitis trial fails
- Nov 16th, 2026 9:52 am
Aclaris Therapeutics’ mAb fails in Phase II eczema trial
- Nov 16th, 2026 7:58 am
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
- Nov 16th, 2026 7:27 am
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
- Nov 16th, 2026 1:30 am
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
- Nov 16th, 2026 1:28 am
Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Nov 12th, 2026 5:30 am
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
- Nov 6th, 2026 6:40 am
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates
- Nov 5th, 2026 6:35 am
Aclaris: Q3 Earnings Snapshot
- Nov 5th, 2026 5:15 am
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Nov 5th, 2026 4:59 am
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
- Oct 27th, 2026 4:04 pm
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering
- Oct 27th, 2026 8:38 am
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?
- Oct 27th, 2026 6:40 am
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
- Oct 27th, 2026 4:43 am
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
- Oct 27th, 2026 4:00 am
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
- Oct 21st, 2026 6:40 am
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
- Sep 15th, 2026 6:47 am
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- Sep 3rd, 2026 6:00 am
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
- Aug 10th, 2026 7:55 am
Scroll